Fovia Ai to Showcase Optimized AI Visualization at IAIP Exhibit, RSNA 2023
Fovia Ai Provides Efficient AI Results in One Unified Viewer CHICAGO, Nov. 26, 2023 /PRNewswire/ -- Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for over two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced that it will be showcasing AI interaction and visualization of AI results from...
Vieworks Showcases X-ray Imaging Excellence: RSNA 2023 Spotlight
ANYANG, South Korea, Nov. 25, 2023 /PRNewswire/ -- Vieworks, a renowned digital x-ray imaging solutions provider, is set to unveil pioneering advancements at RSNA 2023 in Chicago (Booth 1723, November 26th-29th). Building on the success of prior RSNA exhibitions, Vieworks will present its comprehensive range of DR flat panel detectors (FPDs) catering to general radiography, dynamic applications, and...
DxVx, plans to make a license-in agreement of OVM-200 and conduct clinical trials in Asia
- Final stage in licensing OVM-200 from Oxford Vacmedix in the UK- DxVx plans to proceed its own clinical trials in Asia, including Korea and China SEOUL, South Korea, Nov. 24, 2023 /PRNewswire/ -- DxVx announces today that it will conduct its own clinical trials of OVM-200, an anti-cancer vaccine from Oxford Vacmedix(OVM) by license-in agreement and develop further...
Ascentage Pharma Hosts Ceremony Marking the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication
SUZHOU, China, and ROCKVILLE, Md., Nov. 24, 2023 /PRNewswire/ -- 23 Nov, 2023, on the second anniversary of the initial approval for olverembatinib, Ascentage Pharma hosted a ceremony in Suzhou, China, marking the launch of olverembatinib in a newly approved indication and the dispatch of the first batch of the drug for...
China’s First NDA for a KRAS G12C Inhibitor: NMPA Accepts New Drug Application for GFH925 and Grants GFH925 with Priority Review Designation
SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for GFH925 (IBI351) and granted GFH925 with Priority Review designation, for the treatment of patients with...
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
Iron Deficiency Day unites a strong global coalition raising awareness on the serious health impact of iron deficiency and iron deficiency anemia1 This year, the spotlight is on the importance of early iron deficiency diagnosis and treatment and its impact on quality of life ST. GALLEN, SWITZERLAND, Nov. 24, 2023 /PRNewswire/...
CooperVision to host 3rd APAC Myopia Management Symposium in Taiwan Region
Held in partnership with Universal Eye Center, the hybrid event is expected to host more than 2,000 renowned Myopia Management experts across APAC and globally SINGAPORE, Nov. 24, 2023 /PRNewswire/ -- CooperVision, a global leader in myopia management, will host its coveted 3rd Asia Pacific Myopia Management Symposium (APMMS) at Marriott Taipei on...
Everest Medicines Announces China NMPA’s Approval of Nefecon® for the Treatment of Primary IgA Nephropathy in Adult Patients
--Nefecon® is the first approved medicine with an IgAN indication in China-- --The approval marks a new era of IgAN treatment for Chinese patients-- SHANGHAI, Nov. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today that China's National...
Broncus has announced the acquisition of the entire interest in Hangzhou Jingliang
HANGZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Broncus(2216.HK) is pleased to announce that, on November 23 2023 Broncus Hangzhou (a whollyowned subsidiary of Broncus, as Transferee) has entered into the Equity Transfer Agreement with the shareholders of the Hangzhou Jingliang, to acquire 100% equity interest in it. Broncus is a pioneering medical device company in the field of interventional pulmonology...
China’s First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application...
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for IBI351 (KRAS G12C inhibitor) has been accepted by the Center for Drug Evaluation (CDE)...
